CEO Jeff Shaner received total compensation of $4,864,165 for fiscal year 2025, which is reasonable for the CEO of a $1.5 billion healthcare services company, and the pay mix is well-structured: roughly 69% of his total pay was variable and performance-linked (a $1.5 million cash bonus earned at 200% of target driven by strong revenue and adjusted EBITDA results, plus equity awards split 50/50 between time-based restricted stock and performance stock awards tied to adjusted EBITDA), with only his $750,000 base salary being fixed at 15% of total pay — well within policy. The company's stock gained +433.1% over three years versus a peer median of -4.1%, demonstrating strong alignment between executive rewards and shareholder outcomes; all three executives earned their maximum cash bonuses because Aveanna delivered approximately $2.433 billion in revenue and $320.9 million in adjusted EBITDA, reflecting 20% and 75% year-over-year growth respectively. The prior Say on Pay vote received overwhelming support, the compensation committee retained an independent consultant (Aon), a clawback policy framework is in place through Nasdaq listing requirements, and no problematic pay practices such as tax gross-ups or underwater option repricing are present.

Ernst & Young has audited Aveanna since 2017, giving it approximately 9 years of tenure — well below the 25-year threshold that would raise concerns; the non-audit fees (tax services) of $1,184,085 represent about 31% of total audit fees of $3,804,500, which is below the 50% threshold that would raise independence concerns; EY is a Big 4 firm appropriate for a $1.5 billion company; the audit committee recently completed a required lead partner rotation; and no material financial restatements are disclosed.